Dexmedetomidine combined with protective lung ventilation strategy provides lung protection in patients undergoing radical resection of esophageal cancer with one-lung ventilation.
10.12122/j.issn.1673-4254.2020.07.15
- Author:
Zheng GONG
1
;
Xiaomao LONG
2
;
Huijun WEI
1
;
Ying TANG
1
;
Jun LI
1
;
Li MA
1
;
Jun YU
3
Author Information
1. Department of Anesthesiology, Nanning 530021, China.
2. Department Cardiothoracic Surgery, People's Hospital of Guangxi Autonomous Region, Nanning 530021, China.
3. People's Hospital of Guangxi Autonomous Region, Nanning 530021, China.
- Publication Type:Journal Article
- Keywords:
dexmedetomidine;
esophageal cancer;
lung protection;
perioperative period;
pulmonary protective ventilation strategy
- MeSH:
Dexmedetomidine;
Esophageal Neoplasms;
therapy;
Humans;
Lung;
Malondialdehyde;
One-Lung Ventilation
- From:
Journal of Southern Medical University
2020;40(7):1013-1017
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effect of dexmedetomidine combined with pulmonary protective ventilation against lung injury in patients undergoing surgeries for esophageal cancer with one-lung ventilation (OLV).
METHODS:Forty patients with undergoing surgery for esophageal cancer with OLV were randomly divided into pulmonary protective ventilation strategy group (F group) and dexmedetomidine combined with protective ventilation strategy group (DF group; =20). In F group, lung protective ventilation strategy during anesthesia was adopte, and in DF group, the patients received intravenous infusion of dexmedetomidine hydrochloride (0.3 μg · kg ·h) during the surgery starting at 10 min before anesthesia induction in addition to protective ventilation strategy. Brachial artery blood was sampled before ventilation (T), at 30 and 90 min after the start of OLV (T and T, respectively) and at the end of the surgery (T) for analysis of superoxide dismutase (SOD), malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), arterial oxygenation pressure (PaO), oxygenation index (OI) and lung compliance (CL).
RESULTS:At the time points of T, T and T, SOD level was significantly higher and IL-6 level was significantly lower in the DF group than in F group ( < 0.05). The patients in DF group showed significantly higher PaO, OI and CL index than those in F group at all the 3 time points.
CONCLUSIONS:Dexmedetomidine combined with pulmonary protective ventilation strategy can reduce perioperative lung injury in patients undergoing surgery for esophageal cancer with OLV by suppressing inflammation and oxidative stress to improve lung function and reduce adverse effects of the surgery.
